Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We enclose herewith the transcript of the 'Q2 FY2022 Earnings Conference Call' which was hosted by the Company on Friday, 12th November, 2021. The said transcript shall also be made available on the website of the Company. Kindly take the same on record.
Earnings Call for Q2FY22 of Alkem Laboratories
Conference Call with Alkem Laboratories Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript. Q2FY22 Quarterly Result Announced for Alkem Laboratories Ltd.
Highlights: Q2FY22 financial performance: Total Revenue from Operations was Rs 28,000 million, year-on-year growth of 18.5% India sales were Rs 19,605 million, year-on-year growth of 25.9% International sales were Rs 8,052 million, year-on-year growth of 3.4% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 6,244 million, resulting in EBITDA margin of 22.3% vs. 25.4% in Q2FY21. EBITDA grew by 4.0% YoY R&D; expenses for the quarter was Rs 1,407 million, or 5.0% of total revenue from operations compared to Rs 1,393 million in Q2FY21 at 5.9% of total revenue from operations Profit before tax (PBT) was Rs 5,815 million, a growth of 6.2% compared to Q2FY21 Net Profit (after Minority Interest) was Rs 5,443 million, year-on-year growth of 15.3% H1FY22 financial performance: Total Revenue from Operations was Rs 55,314 million, year-on-year growth of 27.0% India sales were Rs 38,702 million, year-on-year growth of 42.7% International sales were Rs 15,955 million, year-on-year growth of 2.0% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 12,172 million, resulting in EBITDA margin of 22.0% vs. 25.8% in H1FY21. EBITDA grew by 8.5% YoY R&D; expenses for H1FY22 was Rs 2,590 million, or 4.7% of total revenue from operations compared to Rs 2,579 million in H1FY21 at 5.9% of total revenue from operations Profit before tax (PBT) was Rs 11,377 million, a growth of 9.3% compared to H1FY21 Net Profit (after Minority Interest) was Rs 10,124 million, year-on-year growth of 13.2% Commenting on the results, Sandeep Singh, Managing Director, Alkem said, “First six months of the financial year has been a very healthy period for the Company’s India business with over 40% YoY growth mainly driven by the acute therapies. Even in chronic therapies and trade generic business, the Company continues to grow ahead of the market. In the US business, new product launches have helped to offset significant pricing pressure in the base business. Our continuous efforts towards cost optimization and driving process efficiencies are also showing good results with improvement in profitability.” Result PDF Alkem Laboratories Ltd - 539523 - Closure of Trading Window
We refer to our earlier communication dated 27th September, 2021 regarding closure of trading window (for the purpose of financial results for the quarter ended 30th September, 2021) starting from 29th September, 2021 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended 30th September, 2021 are communicated to the Stock Exchanges. The Financial Results of the Company for the quarter and half year ended 30th September, 2021 having been communicated to the Stock Exchanges, today i.e. 12th November, 2021, the trading window shall open on 15th November, 2021. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q2FY22 and H1FY22 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Results- Financial Results For Quarter And Half Year Ended September 30, 2021
In continuation of our letter dated 02nd November, 2021 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2021, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 12th November, 2021. The meeting of the Board of Directors of the Company commenced at 10.00 A.M and concluded at 12.30 P.M. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Board Meeting Outcome for Outcome Of Board Meeting Dated 12/11/2021
The Board of Directors at its meeting held today i.e. 12th November, 2021, has approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2021. Accordingly, we are enclosing herewith Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2021 and the Limited Review Report of the Statutory Auditors of the Company. The meeting of the Board of Directors of the Company commenced at 10 am and concluded at 12.30 pm. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q2FY22 and H1FY22 financial results will be held on Friday, 12th November, 2021 at 08.00 P.M. Please find attached herewith the conference call details. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of The Company Scheduled To Be Held On Friday, 12Th November, 2021.
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2021. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Demise
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we regret to inform you of the sad demise of Mr. Dhananjay Kumar Singh, Joint Managing Director of the Company on 28th October, 2021. Mr. Dhananjay Kumar Singh had been on the Board of the Company since the year 1988. The Company places on record his contribution in the growth of the Company and conveys deep sympathy, sorrow and condolences towards his demise. Request you to kindly take the same on record.